Japanese Study Indicates Lambda Could be Resistant to Vaccines

Japanese Study Indicates Lambda Could be Resistant to Vaccines

The SARS-CoV-2 Lambda Variant—also known as lineage C.37—is a variant of the novel coronavirus that causes COVID-19. It was first detected in Peru in December 2020. On June 14, the World Health Organization (WHO) named it the Lambda variant and designated it as a variant of interest. It has since spread to 30 countries around the world, and it may be deemed more resistant to COVID-19 vaccines as compared to other strains. It’s also suggested that the Lambda variant could be more infectious than the Alpha or Gamma variant. Now a new study led by prominent Japanese researchers and published in bioRxiv, a preprint server, used molecular phylogenetic analysis to investigate the evolutionary elements of the Lambda variant of SARS-CoV-2. 

The research team is led by So Nakagawa, Molecular Life Science Department, Tokai University School of Medicine; Kei Sato, Systems Virology, Department of Infectious Disease Control, International Research Center for Infectious Diseases, The Institute of Medical Science, the University of Tokyo; and Kenzo Tokunaga, Department of Pathology, National Institute of Infectious Diseases. The team revealed recently that the insertion of RSYLTPGD246-25...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee